Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes a randomized, open-label trial

Diabetes Care

Volumn 35, Issue 10, 2012, Pages 1986-1993

  Pratley, Richard E ^a   Nauck, Michael A ^b   Bailey, Timothy ^c   Montanya, Eduard ^d   Filetti, Sebastiano ^e   Garber, Alan J ^f   Thomsen, Anne B ^g   Furber, Sabina ^g   Davies, Melanie ^h  

^a FLORIDA HOSPITAL   (United States)

^b Diabetes Center   (Germany)

^c AMCR Institute   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g NOVO NORDISK A S   (Denmark)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREATITIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THYROID TUMOR; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; METFORMIN; NAUSEA; PATIENT SATISFACTION; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84866650686     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2113     Document Type: Article

References (32)

1. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11(Suppl. 3): 26-34
2. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
3. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-2635
4. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100
5. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treatedwithmetformin and a sulfonylurea. Diabetes Care 2005;28: 1083-1091
6. Bergenstal RM, Wysham C, Macconell L, et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-439
7. Drucker DJ, Buse JB, Taylor K, et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250
8. Buse JB, Nauck M, Forst T, et al. Efficacy and safety of exenatide onceweekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study (Abstract). Diabetologia 2011;54 (Suppl. 1):S38 [Abstract 75]
9. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24: 537-550
10. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes ObesMetab 2008; 10:959-969
11. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-168
12. DeFronzo RA, Hissa MN, Garber AJ, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabeteswith metformin alone. Diabetes Care 2009;32: 1649-1655
13. Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94: 4810-4819
14. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patientswith inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-267
15. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
16. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple- dose study. Horm Metab Res 2007;39: 218-223
17. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368-373
18. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122 (Suppl.):S3-S10
19. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705
20. Pratley R, Nauck M, Bailey T, et al.; 1860- LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination withmetformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407
21. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
22. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705-714
23. Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011;28:333-337
24. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990;7:445-451
25. Bradley C. The DTSQ; revised March 2011. Available from http://www.healthpsychologyresearch.com/Admin/ uploaded/Summary/dtsq%20summary% 20rev-24.3.11.pdf. Accessed December 19, 2011
26. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes ObesMetab 2011; 13:348-356
27. Nauck M, Hermansen K, Frid A, et al. Sustained glycaemic control with 2 years liraglutide and glimepiride treatment (both combined with metformin), achieved with weight loss and less hypoglycaemia with liraglutide; data from the LEAD-2 trial (Abstract). In IDF 2009 20th World Congress Abstract Book. Montreal: IDF, 2009; p. 473 (Poster P-1402)
28. Bergenstal RM, Forti A, Chiasson J, et al. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycaemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial (Abstract). Diabetes 2010;59(Suppl. 1):A16 (Abstract 58-OR)
29. Peyrot M, Rubin RR. How does treatment satisfaction work? Modeling determinants of treatment satisfaction and preference. Diabetes Care 2009;32:1411-1417
30. Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care 2011;34:314-319
31. Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96:853-860
32. Seck T, Nauck M, Sheng D, et al.; Sitagliptin Study 024Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled onmetformin: a 2-year study. Int J Clin Pract 2010;64:562-576